Nusano
  • Company
    • Leadership
    • Medical Iso Advisory Board
    • Strategic Advisory Board
    • West Valley City
  • Technology
  • HALEU
    • Direct Metallization HALEU
    • HALEU Knowledge Center
  • Life Sci
    • Medical Isotopes
    • R&D Collaboration
    • Contact Sales
    • About Nuclear Med
  • Batteries
  • News
    • Press Releases
    • Nu-Blog
    • Events
    • Video
    • Podcast
    • Media Kit
    • Email Sign Up
  • Careers
    • NOW HIRING
    • Mission & Values
    • Life in Utah
    • Careers Email
Select Page
Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes

Nusano Achieves Key Technology Milestone Enabling Simultaneous Production of Multiple Radioisotopes

by Scott Larrivee | Jul 9, 2025 | News

Pairing of custom-built klystrons and fast-pulse modulators enable production of up 12 radioisotopes in a single run Power and efficiency of Nusano system to surpass existing commercial methodologies Beam time reservations and isotope supply agreements underway WEST...
Talk Radioisotopes: Paul Schrimpf, Proprietor & Entrepreneur, Cyrall

Talk Radioisotopes: Paul Schrimpf, Proprietor & Entrepreneur, Cyrall

by Scott Larrivee | Jun 26, 2025 | Podcast

In this episode of Talk Radioisotopes, host Scott Larrivee and guest Paul Schrimpf, Proprietor and Entrepreneur at Cyrall, unpacks what it takes to build and scale a radiopharmaceutical business. With a background spanning Accenture, Prophet, and leadership roles...
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

by Scott Larrivee | Jun 26, 2025 | News

The following is a copy of a press release issued by Cellectar Biosciences Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for...
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

by Scott Larrivee | Jun 19, 2025 | News

Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies  DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement

Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

by Scott Larrivee | Jun 17, 2025 | News

Agreement provides Ratio access to Nusano-produced radioisotopes for oncology diagnostics and therapeutics Accelerates Ratio’s clinical pipeline with copper-64 for PET imaging and lutetium-177 and actinium-225 for targeted therapy Bolsters both companies’...
« Older Entries
Next Entries »

Recent Posts

  • Nusano and Primo Announce Multi-Isotope Supply Agreement
  • Oct. 17-21, 2026 – EANM Annual Congress
  • Nusano’s HALEU Platform Selected for NRIC Nuclear Energy Launch Pad USA Program
  • Nusano Completes Major Milestone Toward Commercial Radioisotope Production
  • BioSpace Previews Nusano Production Facility

Recent Comments

No comments to show.
Nusano
Supplying the fight against cancer & enabling life-changing innovations
  • Follow
  • Follow
  • Follow
  • Follow
Company
about us
Leadership
Contact us
technology

The Nusano Platform
R&D Collaboration

Resources
News
Careers
Suppliers
© 2026 Nusano | Web design
Privacy Policy – Terms of Service